Toward Repurposing Ciclopirox as an Antibiotic against Drug-Resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Antibiotic-resistant infections caused by gram-negative bacteria are a major healthcare concern. Repurposing drugs circumvents the time and money limitations associated with developing new antimicrobial agents needed to combat these antibiotic-resistant infections. Here we identified the off-patent antifungal agent, ciclopirox, as a candidate to repurpose for antibiotic use. To test the efficacy of ciclopirox against antibiotic-resistant pathogens, we used a curated collection of Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates that are representative of known antibiotic resistance phenotypes. We found that ciclopirox, at 5-15 µg/ml concentrations, inhibited bacterial growth regardless of the antibiotic resistance status. At these same concentrations, ciclopirox reduced growth of Pseudomonas aeruginosa clinical isolates, but some of these pathogens required higher ciclopirox concentrations to completely block growth. To determine how ciclopirox inhibits bacterial growth, we performed an overexpression screen in E. coli. This screen revealed that galE, which encodes UDP-glucose 4-epimerase, rescued bacterial growth at otherwise restrictive ciclopirox concentrations. We found that ciclopirox does not inhibit epimerization of UDP-galactose by purified E. coli GalE; however, ΔgalU, ΔgalE, ΔrfaI, or ΔrfaB mutant strains all have lower ciclopirox minimum inhibitory concentrations than the parent strain. The galU, galE, rfaI, and rfaB genes all encode enzymes that use UDP-galactose or UDP-glucose for galactose metabolism and lipopolysaccharide (LPS) biosynthesis. Indeed, we found that ciclopirox altered LPS composition of an E. coli clinical isolate. Taken together, our data demonstrate that ciclopirox affects galactose metabolism and LPS biosynthesis, two pathways important for bacterial growth and virulence. The lack of any reported fungal resistance to ciclopirox in over twenty years of use in the clinic, its excellent safety profiles, novel target(s), and efficacy, make ciclopirox a promising potential antimicrobial agent to use against multidrug-resistant problematic gram-negative pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Repurposing this drug toward drug-resistant bacterial species has also proven to be promising (Carlson-Banning et al., 2013).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Carlson-Banning et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
Construction of Escherichia coli K‐12 in‐frame, single‐gene knockout mutants: the Keio collection
Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K. A., Tomita, M., Wanner, B. L., & Mori, H. (2006) · Molecular Systems Biology · doi:10.1038/msb4100050 · Cited by 7,858 · cited 7×
“Only overexpression of glf or galE is not lethal (Figure 6A) [30,39].”
BackgroundMethodInfluentialUse of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes
Studier, F. W., & Moffatt, B. A. (1986) · Journal of Molecular Biology · doi:10.1016/0022-2836(86)90385-2 · Cited by 6,320 · cited 1×
“coli from Epicentre Biotechnologies (Madison WI), MG1655 and BL21(DE3) [81].”
BackgroundBad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958 · cited 3×
“presently in development are effective against them [4,5].”
BackgroundMethodThe Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762
Raetz, C. R. H., & Whitfield, C. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135414 · Cited by 4,404
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724 · cited 2×
“and 70% of all intensive care unit infections [4].”
BackgroundGlobal Spread of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Naas, T., & Poirel, L. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110655 · Cited by 2,378
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777 · cited 4×
“Repurposing already approved therapies for alternative uses saves both time and money [7].”
BackgroundInfluentialCarbon catabolite repression in bacteria: many ways to make the most out of nutrients
Görke, B., & Stülke, J. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1932 · Cited by 1,701 · cited 4×
“metabolizing it through the Emden-Meyerhof-Parnas (EMP) pathway, and repress other sugar metabolism pathways when it is present [61,62].”
BackgroundMethodInfluential
Cited by
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?
Brown, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4675 · Cited by 359
The challenge of converting Gram‐positive‐only compounds into broad‐spectrum antibiotics
Richter, M. F., & Hergenrother, P. J. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13598 · Cited by 227
Boyd, N. K., Teng, C., & Frei, C. R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.684515 · Cited by 197
Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections
Rangel-Vega, A., Bernstein, L. R., Mandujano-Tinoco, E. A., GarcÃa-Contreras, S. J., & GarcÃa-Contreras, R. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00282 · Cited by 168
“For P. aeruginosa, ciclopirox inhibits pyocyanin and may increase pyoverdine production (Carlson-Banning et al., 2013).”
BackgroundMethodInfluentialRepurposing Salicylanilide Anthelmintic Drugs to Combat Drug Resistant Staphylococcus aureus
Rajamuthiah, R., Fuchs, B. B., Conery, A. L., Kim, W., Jayamani, E., Kwon, B., Ausubel, F. M., & Mylonakis, E. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124595 · Cited by 159
Rifabutin Is Active against Mycobacterium abscessus Complex
Aziz, D. B., Low, J. L., Wu, M.-L., Gengenbacher, M., Teo, J. W. P., Dartois, V. A., & Dick, T. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00155-17 · Cited by 141
Iron at the Centre of Candida albicans Interactions
Fourie, R., Kuloyo, O. O., Mochochoko, B. M., Albertyn, J., & Pohl, C. H. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00185 · Cited by 118
“Repurposing this drug toward drug-resistant bacterial species has also proven to be promising (Carlson-Banning et al., 2013).”
BackgroundThe secondary resistome of multidrug-resistant Klebsiella pneumoniae
Jana, B., Cain, A. K., Doerrler, W. T., Boinett, C. J., Fookes, M. C., Parkhill, J., & Guardabassi, L. (2017) · Scientific Reports · doi:10.1038/srep42483 · Cited by 94
Drug repurposing to fight colistin and carbapenem-resistant bacteria
Peyclit, L., Baron, S. A., & Rolain, J.-M. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00193 · Cited by 91
“This is because this molecule affects a new target, generally independent of the antibiotic target, as we will see below with ciclopirox (Carlson-Banning et al., 2013), gallium (Goss et al.”
BackgroundVinuesa, V., & McConnell, M. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062876 · Cited by 71
“aeruginosa (MICs 10 - >30 μg /mL) with differing antibiotic resistance profiles [27].”
BackgroundInfluentialRepositioning the Old Fungicide Ciclopirox for New Medical Uses
Shen, T., & Huang, S. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160530151209 · Cited by 62
Drug repurposing against antibiotic resistant bacterial pathogens
Aggarwal, M., Patra, A., Awasthi, I., George, A., Gagneja, S., Gupta, V., Capalash, N., & Sharma, P. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116833 · Cited by 62
Al‐Anazi, K. A., & Al-Jasser, A. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00186 · Cited by 63
“It has been found to be effective in the treatment of MDRAB infections (31).”
BackgroundNew Antimicrobial Approaches: Reuse of Old Drugs
Savoia, D. (2015) · Current Drug Targets · doi:10.2174/1389450116666150806124110 · Cited by 53
Zhao, Z., Martin, C., Fan, R., Bourne, P. E., & Xie, L. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0941-9 · Cited by 50
Novel Genes Required for Surface-Associated Motility in Acinetobacter baumannii
Blaschke, U., Skiebe, E., & Wilharm, G. (2021) · Current Microbiology · doi:10.1007/s00284-021-02407-x · Cited by 46
Non-antibiotic antimicrobial interventions and antimicrobial stewardship in wound care
Cooper, R., & Kirketerp‐Møller, K. (2018) · Journal of Wound Care · doi:10.12968/jowc.2018.27.6.355 · Cited by 42
Fayed, E. A., Bayoumi, A. H., Saleh, A. S., Al-Arab, E. M. E., & Ammar, Y. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104742 · Cited by 40
Sousa, S. A., Feliciano, J. R., Pita, T., Soeiro, C. F., Mendes, B. L., Alves, L. G., & Leitão, J. H. (2021) · Antibiotics · doi:10.3390/antibiotics10080942 · Cited by 48
EvgS/EvgA, the unorthodox two-component system regulating bacterial multiple resistance
Zhang, R., & Wang, Y. (2023) · Applied and Environmental Microbiology · doi:10.1128/aem.01577-23 · Cited by 39
“In addition, evgS overexpres sion confers resistance to ciclopirox (84, 85).”
BackgroundFayed, E. A., Al-Arab, E. M. E., Saleh, A. S., Bayoumi, A. H., & Ammar, Y. A. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132839 · Cited by 33
Mihailidou, C., Papakotoulas, P., Papavassiliou, A. G., & Karamouzis, M. V. (2017) · Oncotarget · doi:10.18632/oncotarget.23164 · Cited by 33
“This is indicated as the most important mechanism of CPX’s action [17].”
BackgroundRetractedVrâncianu, C. O., Dobre, E.-G., Gheorghe, I., Barbu, I. C., Cristian, R. E., & Chifiriuc, M. C. (2021) · Microorganisms · doi:10.3390/microorganisms9040730 · Cited by 37
“Several drugs administered either alone or in conjunction with classical antibiotics have been shown to be effective in removing resistance in CRE, such as antiretroviral compounds (Zidovudine) [215,216], antifungals (Cyclopirox) [217,218], anticancer compounds (Gallium, Mitotane, Tamoxifen) [219–221], and antidepress…”
BackgroundHigh‐Yield, Magnetic Harvesting of Extracellular Outer‐Membrane Vesicles from Escherichia coli
Shi, R., Dong, Z., Ma, C., Wu, R., Lv, R., Liu, S., Ren, Y., Liu, Z., van der Mei, H. C., Busscher, H. J., et al. (2022) · Small · doi:10.1002/smll.202204350 · Cited by 31
Self-citationMolecular basis of the pleiotropic effects by the antibiotic amikacin on the ribosome
Seely, S. M., Parajuli, N. P., Tarafder, A. D., Ge, X., Sanyal, S., & Gagnon, M. G. (2023) · Nature Communications · doi:10.1038/s41467-023-40416-5 · Cited by 30
“This approach represents a promising strategy to circumvent the spread of resistance to the drugs currently in use 44,45 .”
Fujimura, K., Wang, H., Watson, F., & Klemke, R. L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2873 · Cited by 30
“synthesis of cancer-related proteins, and are the only proteins known to be modified by hypusination [11-13].”
Superbugs: a constraint to achieving the sustainable development goals
Mohsin, S., & Amin, M. N. (2023) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-023-01036-7 · Cited by 34
Repurposing nonantibiotic drugs as antibacterials
Thakare, R., Kaul, G., Shukla, M., Kesharwani, P., Srinivas, N., Dasgupta, A., & Chopra, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818480-6.00005-9 · Cited by 27
Reprogramming of antibiotics to combat antimicrobial resistance
Dubey, K. K., Indu, & Sharma, M. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000168 · Cited by 26
Ma, L. M., Gao, Y., & Maresso, A. W. (2015) · Journal of Bacteriology · doi:10.1128/jb.00758-15 · Cited by 27
“and ELZ4486) (21) were generously provided by Lynn Zechiedrich (Bay-”
Suay‐García, B., Falcó, A., Bueso-Bordils, J. I., Antón-Fos, G. M., Pérez‐Gracia, M. T., & Aleman, P. (2020) · Pharmaceuticals · doi:10.3390/ph13120431 · Cited by 23
“aeruginosa [42] Diflunisal Anti-inflammatory MRSA [43] Statins Hypolipidemic P.”
BackgroundAloni-Grinstein, R., Mamroud, E., & Gal, Y. (2025) · Microorganisms · doi:10.3390/microorganisms13092115 · Cited by 22
“Another key mechanism of ciclopirox is iron chelation [17], a critical factor for bacterial virulence and host defense [18].”
Bonaventura, G. D., Lupetti, V., Fabritiis, S. D., Piccirilli, A., Porreca, A., Nicola, M. D., & Pompilio, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095029 · Cited by 22
“It has recently been found to have considerable potential to act against both Gram-positive and Gram-negative bacterial pathogens [20,28].”
BackgroundResultIn vitro evaluation of ciclopirox as an adjuvant for polymyxin B against gram-negative bacteria
Kim, K.-S., Kim, T., & Pan, J. (2015) · The Journal of Antibiotics · doi:10.1038/ja.2014.164 · Cited by 20
Das, R., Kotra, K., Singh, P., Loh, B., Leptihn, S., & Bajpai, U. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00559-8 · Cited by 19
Davison, J. R., Lohith, K., Wang, X., Bobyk, K. D., Mandadapu, S. R., Lee, S.-L., Cencic, R., Nelson, J., Simpkins, S. W., Frank, K. M., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02635-16 · Cited by 16
In Vitro and In Vivo Activity of AS101 against Carbapenem-Resistant Acinetobacter baumannii
Yang, T.-Y., Tseng, S., Dlamini, H. N., Lu, P., Lin, L., Wang, L., & Hung, W. (2021) · Pharmaceuticals · doi:10.3390/ph14080823 · Cited by 15
“used a substructure-based literature search that led to the identification of ciclopirox, an off-patent, topical antifungal drug that was developed approximately forty years ago [26].”
MethodChandrika, N. T., Fosso, M. Y., Alimova, Y. V., May, A., González, O. A., & Garneau‐Tsodikova, S. (2019) · MedChemComm · doi:10.1039/c9md00074g · Cited by 13
Lim, N. S. J., Sham, A., Chee, S. M. L., Chan, C. K., & Raghunath, M. (2016) · Wound Repair and Regeneration · doi:10.1111/wrr.12463 · Cited by 12
Singh, S., Goo, J.-I., Noh, H., Lee, S. J., Kim, M. W., Park, H., Jalani, H. B., Lee, K., Kim, C., Kim, W.-K., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.12.052 · Cited by 13
Sugar and iron: Toward understanding the antibacterial effect of ciclopirox in Escherichia coli
Conley, Z. C., Carlson-Banning, K. M., Carter, A. G., de la Cova, A., Song, Y., & Zechiedrich, L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210547 · Cited by 15
Self-citationA Brief Study on Drug Repurposing: New Way of Boosting Drug Discovery
Mazumder, R., KAUSHIK, K. K., Debnath, A., & Patel, M. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220901170016 · Cited by 13
Drug Repurposing Patent Applications April–June 2018
Mucke, H. A. (2018) · Assay and Drug Development Technologies · doi:10.1089/adt.2018.29081.pq2 · Cited by 8
Cho, H., & Kim, K.-S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030552 · Cited by 8
“CPX has been repurposed as an anticancer [34–36], diabetes mellitus [37,38], antiviral— including herpes simplex virus (HSV) [39] and HIV [40,41]—and antibacterial agent [28,42,43].”
BackgroundMethodMurray, A. K., Zhang, L., Snape, J., & Gaze, W. H. (2023) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2023.100184 · Cited by 9
Novel and emerging antimicrobial strategies in the management of oral infections
Ünlü, Ö., Yakar, N., & Kantarcı, A. (2025) · Periodontology 2000 · doi:10.1111/prd.70015 · Cited by 8
War and peace: exploring microbial defence systems as a source of new antimicrobial therapies
Dyson, P. J., Banat, I. M., & Quinn, G. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1504901 · Cited by 8
Role of acid responsive genes in the susceptibility of Escherichia coli to ciclopirox
Shin, J., Cho, H., Kim, S., & Kim, K.-S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.063 · Cited by 8
Exploring Cytotoxic Potential of Ciclopirox on Colorectal Cancer Cells by In-Silico Methodology
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac126.72877310 · Cited by 5
Zakaria, A. S., Edward, E. A., & Mohamed, N. M. (2019) · Microbiology and Biotechnology Letters · doi:10.4014/mbl.1908.08002 · Cited by 4
“A volume of 100 μl of 18 μg/ml ciclopirox was then added to each well [2].”
BackgroundMethodInfluentialRevisiting the Fight Against Acinetobacter baumannii: Emerging Non-Antibiotic Strategies
Montini, V. H., Buso, L. S., Takata, P. H., Santos, G. H. M., Gonçalves, B. C., Endo, T. H., Santos, M. H. D. M., Vespero, E. C., Kobayashi, R. K. T., & Nakazato, G. (2026) · Antibiotics · doi:10.3390/antibiotics15030281 · Cited by 3
“…sensing suppression, biofilm formation inhibition, alteration of cell membrane charge [92] Ciclopirox Antifungal Alterations in the cell wall [93] Ebselen Antioxidant Induction of oxidative stress [94] Disulfiram Alcoholism treatment Iron chelation [95] Tamoxifen Antineoplastic Alterations…”
Guo, S., Li, L., Zhang, Q., Liu, H., Yao, X., Liang, L., & Chen, C. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1669585 · Cited by 3
Vrâncianu, C. O., Dobre, E.-G., Gheorghe, I., Barbu, I. C., Cristian, R.-E., & Chifiriuc, M. C. (2021) · International Electronic Conference on Microbiology (ECM) · doi:10.3390/proceedings2020066025 · Cited by 3
“Ciclopirox effectively inhibits CRE growth despite resistant status by interfering with galactose metabolism and LPS biosynthesis [19].”
BackgroundKoçak, E., & Özkul, C. (2021) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2021.00008 · Cited by 2
Breaking the Toxicity-Efficacy Dilemma of Polymyxins: Advances in Synergists
Cai, Z., Zhang, Y., Xin, Y., Han, L., Xu, B., Du, M., & Zhao, Y. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00782 · Cited by 2
A Simple and Rapid Microscale Method for Isolating Bacterial Lipopolysaccharides
Grumov, D. A., Kostarnoy, A. V., Gancheva, P. G., & Kondratev, A. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126345 · Cited by 2
The Battle Against Antibiotic Resistance: Novel Therapeutic Options for Acinetobacter baumannii
Emami, A., Pirbonyeh, N., & Javanmardi, F. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003617 · Cited by 1
Gold( i )-catalyzed synthesis of N -alkenyl 2-pyridonyl sec -amines
Karatavuk, A. O. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob00815d · Cited by 1
Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance
Gatadi, S., Kumar, N. P., Sridevi, B., Borra, P. B., Thapar, P., & Wani, A. (2026) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2026.16158 · Cited by 1
“In vitro studies of a PEGylated colistin prodrug developed by Chongyu Zhu et al., showed similar or better antimicrobial performance against multi drug resistant isolates of Pseudomonas aeruginosa and Acinetobacter baumannii [137].”
Impact of Antimicrobial Drug Efflux Pumps on Antimicrobial Discovery and Development
Li, X.-Z. (2016) · Springer eBooks · doi:10.1007/978-3-319-39658-3_28 · Cited by 1
Lai, Y. (2016) · The Sydney eScholarship Repository (The University of Sydney)
„Der Nagel meines Zeigefingers verfärbt sich zunehmend“
Abeck, D. (2018) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-018-1176-7
Was tun bei Nagelverfärbungen?
Abeck, D. (2019) · hautnah dermatologie · doi:10.1007/s15012-019-3238-7
Paziani, M. H. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2021.tde-29092021-053538 · Cited by 1
Gheorghe, I., Vrâncianu, C. O., Dobre, E.-G., Barbu, I. C., Cristian, R.-E., & Chifiriuc, M. C. (2020) · International Electronic Conference on Microbiology (ECM) · doi:10.3390/ecm2020-07093
Mechanisms and Possible Strategies to Fight Against the Antibiotic Resistance
Hossain, M. A., & Kamrujjaman, M. (2023) · Asian Science Bulletin · doi:10.3923/asb.2023.31.46
“Moreover, this ligand-based pharmacophore-modeling using approved drugs has helped to get lead compounds against MRSA 110 , S. aureus inhibitors 111 and inhibitors of galactose metabolism and lipopolysaccharide biosynthesis in Gram-negative microbes that are drug-resistant 112 .”
BackgroundFar, M. S. E., Kassem, M. A., Edward, E. A., Evans, B. A., Baker, D., & Zakaria, A. S. (2025) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-025-00829-0
“Strikingly, in our study, ciclopirox exerted significant antibacterial activity against the tested MDRAB isolates with MIC values ranging between 4.875 and 9.75 µg/mL. Kimberly et al. reported a comparable MIC range (5–7 µg/mL) of ciclopirox against MDRAB strains [118].”
InfluentialNayak, S., Girmay, S., Byun, H. J., Kim, S. S., Yu, S., Hwang, J. Y., Kim, H. J., Lee, H., Lee, J., Lee, H., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00556
Evaluation of In Vitro Efficiency of Ciclopirox Against Yersinia pestis and Francisella tularensis
Hefetz, I., Ber, R., Gur, D., & Gal, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27042081
“Other studies indicate that ciclopirox’s primary antibacterial (and antifungal) mechanism of action involves iron chelation [7,8].”
InfluentialDrug repurposing to fight against multidrug-resistant bacteria
Peyclit, L. (2020) · theses.fr (ABES) · doi:10.70675/f0f87cfbz0f3dz44edzbc40z7d3c55d221d1
Mian, M. M., Faisal, S. S. M., & Ibrahim, M. (2026) · Microbial Bioactives · doi:10.25163/microbbioacts.9110624
Liu, R., Jin, G., Yu, F., Tan, H., Yuan, F., Zhang, P., Chen, Y., Xiao, L., & Yang, X. (2026) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-026-00872-5
“This geographic signature is further elaborated by the GWAS-based enrichment of distinct metabolic pathways in country-specific comparisons, suggesting that distinct subpopulations may undergo divergent functional trajectories within their respective healthcare ecosystems [69–72].”
Zhu, Z., Long, T., Wang, B., Ding, W., Yan, Y., Wen, Y., Zhao, Y., Zhu, J., Wang, L., Lv, J., et al. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00506-26
“…genes implicated in inner OS biosynthesis ( waaA , waaC , waaE , waaF , waaQ , gmhB , and gmhD ) (19–21), seven genes associated with outer OS biosynthesis ( wabG , wabH , wabI , wabJ , wabN , galU , and ugd ) (19, 22), and one gene associated with the ligation of OS and O-antigen ( waaL ) (19).”
Karatavuk, A. O. (2026) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.70240
Ali, B. F., Al‐Refai, M., Al-Masri, E., Geyer, A., Ivlev, S. I., Aljaar, N., & Shuaib, A. (2026) · Chemical Data Collections · doi:10.1016/j.cdc.2026.101269
DRUGS REPURPOSING: THE HOPE FOR NEW THERAPEUTIC APPLICATIONS
(2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.73s.133
Target-centric drug repurposing: a next-generation approach to confront antimicrobial resistance
Gogoi, I., Saikia, S., & Chetia, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44748-8.00024-5
Metadata
- Authors
- Carlson-Banning, K. M., Chou, A., Liu, Z., Hamill, R. J., Song, Y., & Zechiedrich, L.
- Affiliations
- Baylor College of Medicine (US)
- Michael E. DeBakey VA Medical Center (US)
- Corresponding author
- Zechiedrich, Lynn
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-07-23
- Volume
- 8
- Issue
- 7
- Pages
- e69646
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3720592
- OpenAlex
- W2023096091
- Cited by
- 73
- References
- 87
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 12 · 2020: 5 · 2019: 6 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 6 · 2014: 1
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health (NIH T32, NIH-R01, T32 AI55413)
- National Institute of Allergy and Infectious Diseases (T32 AI55413, R01AI054830, R21AI088123, T32AI055413)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antimicrobial agents and applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- ciclopirox, drug repurposing, antibiotic resistance, Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, gales, UDP-glucose 4-epimerase, galactose metabolism, lipopolysaccharide biosynthesis, galU, multidrug-resistant Gram-negative bacteria, minimum inhibitory concentration
- MeSH terms
- Ciclopirox, Anti-Bacterial Agents, Ciprofloxacin, Drug Resistance, Microbial, Escherichia coli, Galactose, Humans, Hydrogen Peroxide, Iron, Klebsiella pneumoniae, Lipopolysaccharides, Microbial Sensitivity Tests, Mutation, Phenotype, Pyridones, Drug Resistance, Bacterial, Escherichia coli Proteins, Acinetobacter baumannii, Microbial Viability, Biosynthetic Pathways, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.